Primary Renal Lymphoma on a 48 Year Old Woman
NCT06525467 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1
Last updated 2024-07-29
Summary
A 48-year-old female presented to our hospital with the following medical conditions: Systemic arterial hypertension in treatment. She denies any allergies or surgical history.
She reports a history of asthenia and adynamia for 3 months, accompanied by intermittent pain in the left flank. She denies hematuria, fever or weight loss. She underwent an enhanced CT examination at the local hospital, and a mass (10 x 9 cm in diameter) was noted in the left kidney.
Conditions
- Renal Lymphoma
Interventions
- PROCEDURE
-
radical nephrectomy
open radical nephrectomy and lymph node dissection.
Sponsors & Collaborators
-
Instituto Mexicano del Seguro Social
lead OTHER_GOV
Eligibility
- Min Age
- 48 Years
- Max Age
- 48 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-06-22
- Primary Completion
- 2024-06-22
- Completion
- 2024-06-22
Countries
- Mexico
Study Locations
More Related Trials
-
Danish Elder Lymphoma Patient Hematopoietic Investigation
NCT05245487 ·Status: RECRUITING
-
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas
NCT04520529 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Lymphoma in the Orbit
NCT01302912 ·Status: UNKNOWN
-
Identification of Occupational Exposures in Acute Hematologic Malignancy
NCT03316209 ·Status: COMPLETED
-
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
NCT01185262 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN
-
Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma
NCT01316523 ·Status: TERMINATED ·Phase: PHASE2
-
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
NCT06475469 ·Status: RECRUITING ·Phase: NA
-
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
NCT01596127 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
NCT01938001 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
NCT01124526 ·Status: COMPLETED ·Phase: PHASE4
-
A Real-World Study on Extranodal Lymphoma
NCT06573099 ·Status: NOT_YET_RECRUITING
-
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
NCT00005589 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT
NCT02267915 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
NCT00856245 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
NCT00238238 ·Status: COMPLETED ·Phase: PHASE2
-
Application of Telemedicine to the Management of Aggressive Lymphomas
NCT03336138 ·Status: COMPLETED ·Phase: NA
-
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089 ·Status: COMPLETED ·Phase: PHASE2
-
Chronic and Late Effects of Non-Hodgkin's Lymphoma and Its Treatment in Long Term Survivors
NCT00001301 ·Status: COMPLETED
-
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108 ·Status: RECRUITING ·Phase: PHASE1/PHASE2